Huaxi MR Research Center (HMRRC), Department of Radiology, Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, China.
Department of Clinic Medical Center, Dazhou Central Hospital, Dazhou, China.
Front Immunol. 2021 Nov 25;12:790674. doi: 10.3389/fimmu.2021.790674. eCollection 2021.
Glioblastoma (GBM) is the most common malignant tumor of the central nervous system with poor prognosis. Although the field of immunotherapy in glioma is developing rapidly, glioblastoma is still prone to recurrence under strong immune intervention. The major challenges in the process of immunotherapy are evaluating the curative effect, accurately distinguishing between treatment-related reactions and tumor recurrence, and providing guidance for clinical decision-making. Since the conventional magnetic resonance imaging (MRI) is usually difficult to distinguish between pseudoprogression and the true tumor progression, many studies have used various advanced imaging techniques to evaluate treatment-related responses. Meanwhile, criteria for efficacy evaluation of immunotherapy are constantly updated and improved. A standard imaging scheme to evaluate immunotherapeutic response will benefit patients finally. This review mainly summarizes the application status and future trend of several advanced imaging techniques in evaluating the efficacy of GBM immunotherapy.
胶质母细胞瘤(GBM)是中枢神经系统最常见的恶性肿瘤,预后较差。尽管神经胶质瘤的免疫治疗领域发展迅速,但在强烈的免疫干预下,胶质母细胞瘤仍容易复发。免疫治疗过程中的主要挑战是评估疗效,准确区分治疗相关反应与肿瘤复发,并为临床决策提供指导。由于常规磁共振成像(MRI)通常难以区分假性进展和真正的肿瘤进展,因此许多研究使用各种先进的成像技术来评估治疗反应。同时,免疫治疗疗效评估标准不断更新和完善。一个标准的成像方案来评估免疫治疗反应最终将使患者受益。本综述主要总结了几种先进的成像技术在评估 GBM 免疫治疗疗效中的应用现状和未来趋势。